Health Care & Life Sciences » Pharmaceuticals | Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
91,476.00
97,690.00
306.20
40,499.50
191,527.00
483,718
Total Accounts Receivable
-
-
7.30
-
-
-
Other Current Assets
765.00
1,656.00
50.00
708.00
485.00
1,483
Total Current Assets
92,241.00
99,346.00
363.60
41,207.50
192,012.00
485,201
Net Property, Plant & Equipment
1,553.00
1,024.00
-
2.90
301.00
227
Other Assets
1,409.00
305.00
-
-
-
-
Total Assets
95,203.00
100,675.00
363.60
41,210.40
192,313.00
485,428
ST Debt & Current Portion LT Debt
9,493.00
9,256.00
49,095.20
-
-
Accounts Payable
6,589.00
3,139.00
102.30
762.00
1,929.00
Other Current Liabilities
16,125.00
18,494.00
79.50
4,037.90
8,125.00
Total Current Liabilities
32,207.00
30,889.00
49,276.90
4,799.90
10,054.00
Long-Term Debt
13,905.00
4,650.00
-
-
-
Total Liabilities
46,112.00
35,539.00
49,276.90
4,799.90
10,054.00
Common Equity (Total)
49,091.00
65,136.00
48,913.40
36,410.50
182,259.00
Total Shareholders' Equity
49,091.00
65,136.00
48,913.40
36,410.50
182,259.00
Total Equity
49,091.00
65,136.00
48,913.40
36,410.50
182,259.00
Liabilities & Shareholders' Equity
95,203.00
100,675.00
363.60
41,210.40
192,313.00

About Madrigal Pharmaceuticals

View Profile
Address
200 Barr Harbor Drive
West Conshohocken Pennsylvania 19428
United States
Employees -
Website http://www.madrigalpharma.com
Updated 07/08/2019
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.